Hypertension in Children and Young People at Risk of Autosomal Dominant Polycystic Kidney Disease
NCT ID: NCT07260071
Last Updated: 2025-12-02
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
200 participants
Study Classification
OBSERVATIONAL
Study Start Date
2025-08-15
Study Completion Date
2028-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this project is to measure the prevalence of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and hypertension in the general population of children and young people at risk of ADPKD, using magnetic resonance imaging (MRI) for rapid diagnosis alongside genetic testing. The main question it aims to answer is:
What is the prevalence of hypertension in a population sample of adolescents with ADPKD?
Participants will have the following measurements performed:
* Height and weight.
* Blood pressure.
* Non-invasive measurement of arterial stiffness.
* Cardiac and renal MRI.
* Blood sample.
* Genetic testing.
What is the prevalence of hypertension in a population sample of adolescents with ADPKD?
Participants will have the following measurements performed:
* Height and weight.
* Blood pressure.
* Non-invasive measurement of arterial stiffness.
* Cardiac and renal MRI.
* Blood sample.
* Genetic testing.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
2D-speckle Tracking in Pediatric Renal Chronic Disease
NCT04897672
Chronic Renal Disease
Chronic Renal Insufficiency
Congenital Heart Disease
COMPLETED
Estimation of Kidney Function Through Combination of Renal Biomarkers in Blood and Urine of Healthy Infants and Children.
NCT03751397
Renal Biomarkers in Children
COMPLETED
Contribution of Multimodal Imaging in Early Coarctation
NCT05203874
Aortic Coarctation
Congenital Heart Disease
UNKNOWN
Acute Kidney Injury in Children Operated for Congenital Heart Disease
NCT01316497
Acute Kidney Injury
COMPLETED
NA
Nephrological Outcome and Associated Congenital Anomalies in Pediatric Patients with Horseshoe Kidney
NCT06728007
Horseshoe Kidney
RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
INTRODUCTION Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the commonest genetic cause of chronic kidney disease. Despite being inherited, most people do not get symptoms until adulthood with mean age of chronic renal failure around 53 years. Hence, it was thought that there is no need to screen children and young people (C\&YP) at risk of ADPKD until old enough to understand and agree to testing. Linked to this, imaging criteria to diagnose ADPKD mostly cover adult ages.
The validity of this 'adults only' approach is challenged by reports of hypertension in C\&YP with ADPKD, affecting up to a quarter by late teens. This is important in deciding whether to change screening policy because early treatment has the potential to reduce risk of cardiovascular events long-term. Death from cardiovascular disease is still a frequent event in ADPKD families, even before reaching end-stage kidney disease. Not only does the renal damage in ADPKD affect BP and cardiovascular health but there is evidence that ADPKD causes generalised endothelial dysfunction. This provides further justification for good BP control and treatment from the earliest stages of ADPKD.
Currently, it is not known whether the estimated prevalence of hypertension in C\&YP with ADPKD is overestimated because most evidence comes from specialist Paediatric Nephrology centres, where it would be expected that the more severe cases would be managed. This study will determine whether blood pressure (BP) should be screened in all C\&YP at risk, as well as testing the utility of ultrasound and genetic approaches.
This proposed study will be most comprehensive assessment of blood pressure in ADPKD across all age groups. As a result, information gained may revolutionise the approach to the measurement and management of BP in medical practice, particularly in children.
PATIENT AND PUBLIC INVOLVEMENT This study has been set up to specifically consider individuals with ADPKD and so the investigators have designed this study in discussion with The PKD Charity. The investigators will continue to utilise this wealth of patient experience as this study is conducted by keeping the PKD Charity informed of progress, presenting results at patient group meetings and conferences, so that patients are able to see the work that the investigators are doing to improve their understanding of ADPKD. Any publications resulting from this work will be sent to the PKD Charity for inclusion on their website.
A trustee of the PKD charity and patient representative for ADPKD has previously reviewed patient information sheets and consent forms and as a result of helpful comments the investigators have modified the patient information sheet for children.
Lastly these proposals have been previewed as a 'theoretical potential study' on the UK PKD Charity forums: no-one expressed concerns over the study design and over 40 responders expressing immediate interest in participating.
PARTICIPANT SELECTION Source of participants
The study will be advertised on the PKD website, and via social media, leaflets and letters in clinic. This strategy aims to ascertain participants from an unbiased population, to ensure the scientific aims of this study are met which is to determine the true blood pressure levels in C\&YP with ADPKD. In addition, using these channels publicises the study without any pressure on families/children to get involved since they have to make the first contact to express interest. Interested participants or their parents/guardians will be able to contact the research team to find out more about the study. Enquiries about study enrolment will be fielded by the Study Co-ordinator, based at King's College London. The study coordinator can ascertain initial eligibility, whilst referring any queries to the Chief Investigator. If the participant appears to be eligible for the study, the relevant Participant Information Sheet (Parent and Adolescent/16+ versions) can be sent out to the participant and their family. The study coordinator will book an appropriate time for the participant and their parent/guardian to attend their most convenient participating site
Number of participating sites involved: 3
Participant numbers: The study aims to recruit 200 C\&YP in total. This generates a 95% confidence of detecting a difference between populations with hypertension prevalence of 20% (ADPKD) versus 10% with 80% power. Once they have undertaken the full BP and cardiovascular assessment (anticipated over 1-2 visits), participants will only be seen once and will not be required for further follow up. Results of genetic testing are anticipated to be available after 6-12 months.
STUDY PROCEDURES Screening Procedures
Interested participants or their parents/guardians will be able to contact the research team to find out more about the study. Enquiries about study enrolment will be fielded by the Study Co-ordinator, based at King's College London. The study coordinator can ascertain initial eligibility, whilst referring any queries to the Chief Investigator. If the subject appears to be eligible for the study, the relevant Patient Information Sheet (Parent and Adolescent/16+ versions) can be sent out to the participant and their family. All participants that undergo screening will be logged onto a screening log associated with the study.
Once eligibility is confirmed, and the participant has received the PIS, the study coordinator will contact them to book an appropriate time for the participant and their parent/guardian to attend their most convenient participating site.
Participant recruitment The study will be advertised on the PKD website, and via social media, leaflets and letters in clinic. This strategy aims to ascertain participants from an unbiased population, to ensure the scientific aims of this study are met which is to determine the true blood pressure levels in C\&YP with ADPKD. In addition, using these channels publicises the study without any pressure on families/children to get involved since they now have to make the first contact to express interest.
Participants will be offered reimbursement of their reasonable expenses for them and their parent /guardian to attend their chosen participating site.
Participants and their parent/guardian will be sent age appropriate information sheets prior to their first appointment at the hospital and will have at least a week to consider their participation in the study. Written materials will be produced in English. They will be consented by a clinician when they attend for Visit 1 of the study.
Follow up Procedures When the results of the tests are ready, families will be informed of the results with a telephone consultation. If there is no evidence of ADPKD, hypertension or other novel findings, the participant will be discharged. If there is evidence of ADPKD, hypertension or another medical condition, the participant will be followed up in an NHS clinic as per standard of care.
Radiology Assessments MRI will be used to scan the kidneys for evidence of ADPKD and assess the structure and function of the heart. Both regions will be imaged in the same scan session. No contrast will be required.
MRI safety aspects will be handled by the research MRI staff in the study centre. Experienced MRI radiographers will ensure all participants have completed an MRI safety questionnaire prior to their MRI scan as per the Safety Guidelines for Magnetic Resonance Imaging Equipment in Clinical Use, MHRA, February 2021 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\_data/file/958486/MRI\_guidance\_2021-4-03c.pdf.
END OF STUDY DEFINITION
• The date of when all the samples from all patients have been analysed.
ASSESSMENT OF SAFETY
* No particular serious adverse events (SAEs) are expected to occur during this study.
* Where a SAE is related to the study procedures and is an unexpected occurrence (that is, the type of event is not listed in the protocol as an expected occurrence) then it will be reported immediately upon knowledge of the event to R\&D and always within 24 hours. A note will be put in the case report form (CRF) and on the participants medical notes.
* If a SAE/AE occurs that does not require immediate reporting, this will be reported in the participant's CRF and reported to GSTT when copied into the Annual Progress Report.
* All serious adverse events that are to be reported to R\&D will be signed and dated and completed by the Investigator.
* At other sites, the Principal Investigators at all sites must report all SAEs to the Chief Investigator first where possible. The Chief Investigator is then responsible for reporting events to the regulators/R\&D as the sponsor office.
Trial Steering Committee (if applicable) N/A
The validity of this 'adults only' approach is challenged by reports of hypertension in C\&YP with ADPKD, affecting up to a quarter by late teens. This is important in deciding whether to change screening policy because early treatment has the potential to reduce risk of cardiovascular events long-term. Death from cardiovascular disease is still a frequent event in ADPKD families, even before reaching end-stage kidney disease. Not only does the renal damage in ADPKD affect BP and cardiovascular health but there is evidence that ADPKD causes generalised endothelial dysfunction. This provides further justification for good BP control and treatment from the earliest stages of ADPKD.
Currently, it is not known whether the estimated prevalence of hypertension in C\&YP with ADPKD is overestimated because most evidence comes from specialist Paediatric Nephrology centres, where it would be expected that the more severe cases would be managed. This study will determine whether blood pressure (BP) should be screened in all C\&YP at risk, as well as testing the utility of ultrasound and genetic approaches.
This proposed study will be most comprehensive assessment of blood pressure in ADPKD across all age groups. As a result, information gained may revolutionise the approach to the measurement and management of BP in medical practice, particularly in children.
PATIENT AND PUBLIC INVOLVEMENT This study has been set up to specifically consider individuals with ADPKD and so the investigators have designed this study in discussion with The PKD Charity. The investigators will continue to utilise this wealth of patient experience as this study is conducted by keeping the PKD Charity informed of progress, presenting results at patient group meetings and conferences, so that patients are able to see the work that the investigators are doing to improve their understanding of ADPKD. Any publications resulting from this work will be sent to the PKD Charity for inclusion on their website.
A trustee of the PKD charity and patient representative for ADPKD has previously reviewed patient information sheets and consent forms and as a result of helpful comments the investigators have modified the patient information sheet for children.
Lastly these proposals have been previewed as a 'theoretical potential study' on the UK PKD Charity forums: no-one expressed concerns over the study design and over 40 responders expressing immediate interest in participating.
PARTICIPANT SELECTION Source of participants
The study will be advertised on the PKD website, and via social media, leaflets and letters in clinic. This strategy aims to ascertain participants from an unbiased population, to ensure the scientific aims of this study are met which is to determine the true blood pressure levels in C\&YP with ADPKD. In addition, using these channels publicises the study without any pressure on families/children to get involved since they have to make the first contact to express interest. Interested participants or their parents/guardians will be able to contact the research team to find out more about the study. Enquiries about study enrolment will be fielded by the Study Co-ordinator, based at King's College London. The study coordinator can ascertain initial eligibility, whilst referring any queries to the Chief Investigator. If the participant appears to be eligible for the study, the relevant Participant Information Sheet (Parent and Adolescent/16+ versions) can be sent out to the participant and their family. The study coordinator will book an appropriate time for the participant and their parent/guardian to attend their most convenient participating site
Number of participating sites involved: 3
Participant numbers: The study aims to recruit 200 C\&YP in total. This generates a 95% confidence of detecting a difference between populations with hypertension prevalence of 20% (ADPKD) versus 10% with 80% power. Once they have undertaken the full BP and cardiovascular assessment (anticipated over 1-2 visits), participants will only be seen once and will not be required for further follow up. Results of genetic testing are anticipated to be available after 6-12 months.
STUDY PROCEDURES Screening Procedures
Interested participants or their parents/guardians will be able to contact the research team to find out more about the study. Enquiries about study enrolment will be fielded by the Study Co-ordinator, based at King's College London. The study coordinator can ascertain initial eligibility, whilst referring any queries to the Chief Investigator. If the subject appears to be eligible for the study, the relevant Patient Information Sheet (Parent and Adolescent/16+ versions) can be sent out to the participant and their family. All participants that undergo screening will be logged onto a screening log associated with the study.
Once eligibility is confirmed, and the participant has received the PIS, the study coordinator will contact them to book an appropriate time for the participant and their parent/guardian to attend their most convenient participating site.
Participant recruitment The study will be advertised on the PKD website, and via social media, leaflets and letters in clinic. This strategy aims to ascertain participants from an unbiased population, to ensure the scientific aims of this study are met which is to determine the true blood pressure levels in C\&YP with ADPKD. In addition, using these channels publicises the study without any pressure on families/children to get involved since they now have to make the first contact to express interest.
Participants will be offered reimbursement of their reasonable expenses for them and their parent /guardian to attend their chosen participating site.
Participants and their parent/guardian will be sent age appropriate information sheets prior to their first appointment at the hospital and will have at least a week to consider their participation in the study. Written materials will be produced in English. They will be consented by a clinician when they attend for Visit 1 of the study.
Follow up Procedures When the results of the tests are ready, families will be informed of the results with a telephone consultation. If there is no evidence of ADPKD, hypertension or other novel findings, the participant will be discharged. If there is evidence of ADPKD, hypertension or another medical condition, the participant will be followed up in an NHS clinic as per standard of care.
Radiology Assessments MRI will be used to scan the kidneys for evidence of ADPKD and assess the structure and function of the heart. Both regions will be imaged in the same scan session. No contrast will be required.
MRI safety aspects will be handled by the research MRI staff in the study centre. Experienced MRI radiographers will ensure all participants have completed an MRI safety questionnaire prior to their MRI scan as per the Safety Guidelines for Magnetic Resonance Imaging Equipment in Clinical Use, MHRA, February 2021 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\_data/file/958486/MRI\_guidance\_2021-4-03c.pdf.
END OF STUDY DEFINITION
• The date of when all the samples from all patients have been analysed.
ASSESSMENT OF SAFETY
* No particular serious adverse events (SAEs) are expected to occur during this study.
* Where a SAE is related to the study procedures and is an unexpected occurrence (that is, the type of event is not listed in the protocol as an expected occurrence) then it will be reported immediately upon knowledge of the event to R\&D and always within 24 hours. A note will be put in the case report form (CRF) and on the participants medical notes.
* If a SAE/AE occurs that does not require immediate reporting, this will be reported in the participant's CRF and reported to GSTT when copied into the Annual Progress Report.
* All serious adverse events that are to be reported to R\&D will be signed and dated and completed by the Investigator.
* At other sites, the Principal Investigators at all sites must report all SAEs to the Chief Investigator first where possible. The Chief Investigator is then responsible for reporting events to the regulators/R\&D as the sponsor office.
Trial Steering Committee (if applicable) N/A
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Autosomal Dominant Polycystic Kidney Disease (ADPKD
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
CASE_CONTROL
Study Time Perspective
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ADPKD positive
Participants with positive renal MRI and/or genetic test for ADPKD
No interventions assigned to this group
ADPKD negative
Participants with negative renal MRI and genetic test for ADPKD
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 12 - 17 years at the time of consent
* Able to tolerate the key study investigations (office blood pressure measurement, ambulatory blood pressure measurement, MRI and blood test)
* Parent with confirmed clinical diagnosis of ADPKD
* Parent (if child \<16 years) or both parent and young person (if \>=16 years) consents to genetic testing for ADPKD and demonstrates understanding of the implications of this.
* Able to tolerate the key study investigations (office blood pressure measurement, ambulatory blood pressure measurement, MRI and blood test)
* Parent with confirmed clinical diagnosis of ADPKD
* Parent (if child \<16 years) or both parent and young person (if \>=16 years) consents to genetic testing for ADPKD and demonstrates understanding of the implications of this.
Exclusion Criteria
* 18 years or above at the time of study entry
* Unable to tolerate key study investigations
* Presence of associated co-morbidities which make it difficult to interpret results, including congenital cardiac anomalies and known TSC-PKD1 mutations
* Unwilling to undergo genetic testing for ADPKD
* Unable to tolerate key study investigations
* Presence of associated co-morbidities which make it difficult to interpret results, including congenital cardiac anomalies and known TSC-PKD1 mutations
* Unwilling to undergo genetic testing for ADPKD
Minimum Eligible Age
12 Years
Maximum Eligible Age
17 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guy's and St Thomas' NHS Foundation Trust
OTHER
Sponsor Role
collaborator
King's College London
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Manish Sinha, PhD, MRCP (UK), MRCPCH
Role: PRINCIPAL_INVESTIGATOR
King's College London
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Evelina London Children's Hospital
London, , United Kingdom
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United Kingdom
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Ecder T, Schrier RW. Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Nat Rev Nephrol. 2009 Apr;5(4):221-8. doi: 10.1038/nrneph.2009.13.
Reference Type
BACKGROUND
Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dicks E, Parfrey P, Cramer B, Coto E, Torra R, San Millan JL, Gibson R, Breuning M, Peters D, Ravine D. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. 2009 Jan;20(1):205-12. doi: 10.1681/ASN.2008050507. Epub 2008 Oct 22.
Reference Type
BACKGROUND
Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007 Apr 14;369(9569):1287-1301. doi: 10.1016/S0140-6736(07)60601-1.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
https://pkdcharity.org.uk/research/pkd-uk-research/hiya-pkd-study
Polycystic Kidney Disease Charity website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
347395
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
CTT on Renogram as an Early Marker of Significant Obstruction in Uretero-pelvic Junction Syndrome
NCT02812212
RECRUITING
NA
Central Blood Pressure and Pulse Wave Velocity in Kidney Transplant Recipients
NCT04212143
ACTIVE_NOT_RECRUITING
Study of Heat Shock Proteins as Prognostic Factor of Acute Renal Failure in Children (HSP-Study)
NCT00230412
UNKNOWN
Antenatal Investigation of Fetuses With Complex Congenital Heart Defects Using multiOMICS
NCT06705543
RECRUITING
NA
Assessment of Renal Function in Adults Born Preterm: The HAPI-Kidney Study
NCT04735315
ACTIVE_NOT_RECRUITING
Ultrasonography Sensibilized by Oral Hydration and Hydronephrosis in Children.
NCT02086760
WITHDRAWN
NA
Validation of Low Dose CT for Diagnosis of Urolithiasis
NCT03656913
TERMINATED
NA
Severe Sepsis in Children - IMPRESS-C
NCT02598674
WITHDRAWN
Cyanotic Heart Disease and Thrombosis
NCT02716402
COMPLETED
NA
Transcranial Ultrasound Assessment of Cerebral Pulsatility in Shunt Decision-making for Suspected Idiopathic Normal Pressure Hydrocephalus: a Prospective Cohort Study
NCT07285928
NOT_YET_RECRUITING
The Predictive Value of Ureteral Jet Assessment With Ultrasound in Patients Presenting With Acute Renal Colic
NCT02577146
COMPLETED
NA
Computed Tomographic Assessment of Cardiac and Extra Cardiac Vascular Anomalies Associated With Tetralogy of Fallot
NCT05291858
NOT_YET_RECRUITING
The Paediatric Refill Study (PRefill)
NCT02208817
COMPLETED
Hemostatic Profiles in Pediatric CKD
NCT05064267
COMPLETED
Functional MR Urography
NCT00301470
COMPLETED
PHASE4
Improving Phosphate Control in Children With CKD
NCT05439980
RECRUITING
Normal Reference Ranges for Urinary Metabolites and Supersaturation Indices in Pediatric Populations
NCT00591097
COMPLETED
Long Term Impact of Pediatric Acute Renal Injury in Severe Sepsis
NCT02372721
WITHDRAWN
Multiparametric Magnetic Resonance Imaging (MRI) in Medullary Sponge Kidney
NCT05682053
COMPLETED
NA
Quality of Life Among Children With Congenital Heart Disease
NCT01202916
COMPLETED
Prospective Evaluation of Blunt Renal Injury in Children
NCT00855036
TERMINATED
Prospective Pediatric Vesicoureteral Reflux Surgery Database
NCT01373385
COMPLETED
Home Monitoring in Pediatric Heart Failure
NCT05017077
UNKNOWN
NA
MRI Hydronephrosis Study
NCT01588340
WITHDRAWN
NA
Characteristics and Outcomes of Childhood Moyamoya in the UK
NCT02434302
COMPLETED